Amicus Therapeutics (id:6415 FOLD)
9.66 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 3:41:34 PM)
Exchange closed, opens in 1 day 17 hours
1.47 USD (1.47%)
-0.26 USD (-0.26%)
-7.65 USD (-7.65%)
-0.82 USD (-0.82%)
-8.87 USD (-8.87%)
-1.43 USD (-1.43%)
38.20 USD (38.20%)
-39.62 USD (-39.62%)
About Amicus Therapeutics
Market Capitalization 2.89B
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
| Headquarters (address) |
47 Hulfish Street Princeton 08542 NJ United States |
| Phone | 609 662 2000 |
| Website | https://amicusrx.com |
| Employees | 500 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | FOLD |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 9.02 - 14.57 |
| Market Capitalization | 2.89B |
| P/E trailing | -18.94 |
| P/E forward | 60.38 |
| Price/Sale | 5.85 |
| Price/Book | 16.13 |
| Beta | 0.673 |
| EPS | -0.340 |
| EPS United States (ID:6, base:3402) | 24.25 |